I must admit I have been skeptical when it comes to THC-A. I am changing my mind. There just are so, so few THC-A studies. On the other hand, we are missing a lot of data in areas where we see daily success. It just a matter of time.

In my last blog I spoke about young woman with Myasthenia Gravis and her response to THC-A. I am following many children with seizures. There is a very good response rate, well over 50%, but there are kids who do not respond to CBD. I recently was treating a child with CBD unresponsive seizures. We kept doubling the dose and finally gave it a break and substituted low dose THC-A. As with the Myasthenia Gravis patient, the response was very quick.

So, here are two “anecdotal” or “N=1” studies showing the efficacy of THC-A in two fairly different neurological disorders. I will need to spend some time looking into the relationship between acetylcholine and seizures? Anyone out there have some thoughts??

Allan Frankel, MD Dr Allan Frankel is one of the few physicians in the US who truly understands Cannabis as a medicine. All treatments suggested have been well studied. Every patient seen by Dr Frankel is given a personally created Treatment Plan created with the patient's specific issues defined. Plant medicine requires "tuning" of the dosing. Dr Frankel works with his patients thru a messaging portal. The use of this portal, allows quick and simple follow up contact with Dr Frankel. Patients are not charged for these messages, as this is how Dr Frankel has learned what he has learned. Follow up appointments in person or by phone/video are also available when needed

You Might Also Enjoy...

Rationing Health Care

With COVID, we have never been more aware of critical shortages of masks, ventilators, hospital beds, etc., all leading to rationing. In this BLOG, Dr Frankel, examines how rationing in our medical care is a much bigger problem than just face masks.

Cannabis May Prevent COVID-19 Infections

Early studies in both Israel and Canada show findings consistent with CBD's effect on COVID-19's ability to take hold in the lungs or the gastrointestinal tract. If the receptors are reduced, the viral infection and pulmonary toxicity should be reduced.